Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infection Vol. 84; no. 6; pp. 834 - 872
Main Authors:	Tunesi, Simone, Dû, Damien Le, Gualano, Gina, Millet, Joan-Pau, Skrahin, Aliaksandr, Bothamley, Graham, Casas, Xavier, Goletti, Delia, Lange, Christoph, Musso, Maria, Palmieri, Fabrizio, Pourcher, Valérie, Rioux, Christophe, Skrahina, Alena, Veziris, Nicolas, Viatushka, Dzmitry, Jachym-Fréchet, Mathilde, Guglielmetti, Lorenzo, Marigot-Outtandy, Dhiba, Lescure, Xavier, Dubert, Marie, Yazdanpanah, Yazdan, Caumes, Eric, Choinier, Pascaline, Haddad, Elie, Kowalczyk, Jakub, Laurichesse, Hélène, Lesens, Olivier, Aubry, Alexandra, Bonnet, Isabelle, Morel, Florence
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.06.2022 Elsevier
Subjects:	Antitubercular Agents - therapeutic use Hepatitis C - drug therapy Human health and pathology Humans Infectious diseases Life Sciences Pulmonology and respiratory tract Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy MDR antiviral tuberculosis
ISSN:	0163-4453, 1532-2742, 1532-2742
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed a retrospective, multicentre observational cohort study of patients treated concomitantly for multidrug-resistant tuberculosis and HCV-infection between January 2015 and February 2021.ResultsOverall, 23 patients were enrolled across six centres in four countries. Predominant HCV genotype was 3 (40%) and most patients had absent or mild liver fibrosis. All patients completed HCV treatment without interruptions and achieved undetectable plasmatic HCV-RNA from week 12. Sustained virological response was equally obtained for all patients with available results. Among 11 patients who had finished MDR-TB treatment at data censoring, 10 achieved cure and one died. Overall, 18 liver-related adverse events were reported in 48% of patients, the majority (94%) occurring during MDR-TB treatment but before HCV treatment was started. No liver-related serious adverse events or Grade 4 adverse events were reported.ConclusionsConcomitant treatment of HCV and MDR-TB was well tolerated and effective. HCV treatment should be considered in MDR-TB patients to reduce treatment-related hepatotoxicity and prevent progression of HCV-mediated liver disease.
AbstractList	ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed a retrospective, multicentre observational cohort study of patients treated concomitantly for multidrug-resistant tuberculosis and HCV-infection between January 2015 and February 2021.ResultsOverall, 23 patients were enrolled across six centres in four countries. Predominant HCV genotype was 3 (40%) and most patients had absent or mild liver fibrosis. All patients completed HCV treatment without interruptions and achieved undetectable plasmatic HCV-RNA from week 12. Sustained virological response was equally obtained for all patients with available results. Among 11 patients who had finished MDR-TB treatment at data censoring, 10 achieved cure and one died. Overall, 18 liver-related adverse events were reported in 48% of patients, the majority (94%) occurring during MDR-TB treatment but before HCV treatment was started. No liver-related serious adverse events or Grade 4 adverse events were reported.ConclusionsConcomitant treatment of HCV and MDR-TB was well tolerated and effective. HCV treatment should be considered in MDR-TB patients to reduce treatment-related hepatotoxicity and prevent progression of HCV-mediated liver disease.
Author	Choinier, Pascaline Viatushka, Dzmitry Laurichesse, Hélène Millet, Joan-Pau Caumes, Eric Skrahina, Alena Yazdanpanah, Yazdan Morel, Florence Pourcher, Valérie Jachym-Fréchet, Mathilde Lesens, Olivier Musso, Maria Marigot-Outtandy, Dhiba Gualano, Gina Lange, Christoph Aubry, Alexandra Haddad, Elie Casas, Xavier Skrahin, Aliaksandr Lescure, Xavier Rioux, Christophe Dû, Damien Le Guglielmetti, Lorenzo Kowalczyk, Jakub Bonnet, Isabelle Tunesi, Simone Dubert, Marie Veziris, Nicolas Palmieri, Fabrizio Goletti, Delia Bothamley, Graham
Author_xml	– sequence: 1 givenname: Simone orcidid: 0000-0002-4943-4446 surname: Tunesi fullname: Tunesi, Simone organization: Infectious Diseases Unit, ASST Valle Olona, Busto Arsizio, Italy – sequence: 2 givenname: Damien Le orcidid: 0000-0001-9330-019X surname: Dû fullname: Dû, Damien Le organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France – sequence: 3 givenname: Gina surname: Gualano fullname: Gualano, Gina organization: National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy – sequence: 4 givenname: Joan-Pau surname: Millet fullname: Millet, Joan-Pau organization: CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain – sequence: 5 givenname: Aliaksandr surname: Skrahin fullname: Skrahin, Aliaksandr organization: The Republican Research and Practical Center for Pulmonology and TB, Minsk, Belarus – sequence: 6 givenname: Graham surname: Bothamley fullname: Bothamley, Graham organization: Homerton University Hospital, London E9 6SR, UK – sequence: 7 givenname: Xavier surname: Casas fullname: Casas, Xavier organization: Epidemiology Service, Public Health Agency of Barcelona, Spain – sequence: 8 givenname: Delia orcidid: 0000-0001-8360-4376 surname: Goletti fullname: Goletti, Delia organization: National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy – sequence: 9 givenname: Christoph surname: Lange fullname: Lange, Christoph organization: Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany – sequence: 10 givenname: Maria surname: Musso fullname: Musso, Maria organization: National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy – sequence: 11 givenname: Fabrizio orcidid: 0000-0001-8184-6291 surname: Palmieri fullname: Palmieri, Fabrizio organization: National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy – sequence: 12 givenname: Valérie surname: Pourcher fullname: Pourcher, Valérie organization: APHP, Service des Maladies Infectieuses et Tropicales, Sorbonne Université, Site Pitié, Paris, France – sequence: 13 givenname: Christophe surname: Rioux fullname: Rioux, Christophe organization: APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France – sequence: 14 givenname: Alena surname: Skrahina fullname: Skrahina, Alena organization: The Republican Research and Practical Center for Pulmonology and TB, Minsk, Belarus – sequence: 15 givenname: Nicolas orcidid: 0000-0001-5660-6544 surname: Veziris fullname: Veziris, Nicolas organization: Département de Bactériologie, APHP, Groupe Hospitalier Universitaire Sorbonne Université, Site, Paris, Saint-Antoine, France – sequence: 16 givenname: Dzmitry surname: Viatushka fullname: Viatushka, Dzmitry organization: The Republican Research and Practical Center for Pulmonology and TB, Minsk, Belarus – sequence: 17 givenname: Mathilde surname: Jachym-Fréchet fullname: Jachym-Fréchet, Mathilde organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France – sequence: 18 givenname: Lorenzo orcidid: 0000-0003-0886-9635 surname: Guglielmetti fullname: Guglielmetti, Lorenzo email: lorenzo.guglielmetti@aphp.fr organization: Laboratoire de Bactériologie-Hygiène, APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, 91 Boulevard de l'hôpital, Paris Cedex 13 75634, France – sequence: 19 givenname: Dhiba surname: Marigot-Outtandy fullname: Marigot-Outtandy, Dhiba organization: Bligny – sequence: 20 givenname: Xavier surname: Lescure fullname: Lescure, Xavier organization: Paris-Bichat – sequence: 21 givenname: Marie surname: Dubert fullname: Dubert, Marie organization: Paris-Bichat – sequence: 22 givenname: Yazdan surname: Yazdanpanah fullname: Yazdanpanah, Yazdan organization: Paris-Bichat – sequence: 23 givenname: Eric surname: Caumes fullname: Caumes, Eric organization: Paris-Pitié-Salpetrière – sequence: 24 givenname: Pascaline surname: Choinier fullname: Choinier, Pascaline organization: Paris-Pitié-Salpetrière – sequence: 25 givenname: Elie surname: Haddad fullname: Haddad, Elie organization: Paris-Pitié-Salpetrière – sequence: 26 givenname: Jakub surname: Kowalczyk fullname: Kowalczyk, Jakub organization: Mulhouse – sequence: 27 givenname: Hélène surname: Laurichesse fullname: Laurichesse, Hélène organization: Clermont Ferrand – sequence: 28 givenname: Olivier surname: Lesens fullname: Lesens, Olivier organization: Clermont Ferrand – sequence: 29 givenname: Alexandra surname: Aubry fullname: Aubry, Alexandra organization: Paris-CNR Mycobactéries – sequence: 30 givenname: Isabelle surname: Bonnet fullname: Bonnet, Isabelle organization: Paris-CNR Mycobactéries – sequence: 31 givenname: Florence surname: Morel fullname: Morel, Florence organization: Paris-CNR Mycobactéries
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35271917$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-03608140$$DView record in HAL
BookMark	eNqFkktvEzEUhS1URNPCH2CBvITFDH7Nq2ITotIgBbGgILGyPJ5r1WHGTm2nUv49nqZl0UXZ2PL1d46u7_EZOnHeAUJvKSkpofXHbbm1zpSMMFYSXhIiXqAFrTgrWCPYCVpkiBdCVPwUncW4JYR0vKtfoVNesYZ2tFkgt_KFGibrbExBJesd9ganACpN4BI2PuBgjZp2VltXBIgZVPni-jNWbsD6JnhnNV6vfuHcDOjZ4gIv872DdI9c_rj69nuFY9oPh9fopVFjhDcP-zn6-eXyerUuNt-vvq6Wm0KLtkoF7_pKNUMLrBei6_uBtYLzujPa1JWq-16TvNS5lI-NUQSEag1QUvX5ZQ3j5-jD0fdGjXIX7KTCQXpl5Xq5kXON8Jq0VJA7mtn3R3YX_O0eYpKTjRrGUTnw-yhZzdts2dHZ9t0Duu8nGP45P84zA-0R0MHHGMBIbdP9WPN07SgpkXN0civn6OQcXW5F5uiylD2RPro_K_p0FEEe5p2FIKO24DQMNuQs5ODt8_KLJ3I95q-g1fgHDv8T_wXw_sQR
CitedBy_id	crossref_primary_10_1371_journal_pmed_1004121 crossref_primary_10_3390_idr15060066 crossref_primary_10_1136_bmjopen_2022_067065
Cites_doi	10.1016/j.jinf.2019.10.019 10.1016/j.jhep.2019.10.018 10.1128/AAC.01215-19 10.1183/13993003.02089-2018 10.1186/s12879-019-4494-1 10.1093/ofid/ofaa653
ContentType	Journal Article
Contributor	Kowalczyk, Jakub Bonnet, Isabelle Choinier, Pascaline Laurichesse, Hélène Caumes, Eric Yazdanpanah, Yazdan Morel, Florence Dubert, Marie Lesens, Olivier Marigot-Outtandy, Dhiba Aubry, Alexandra Haddad, Elie Lescure, Xavier
Contributor_xml	– sequence: 1 givenname: Dhiba surname: Marigot-Outtandy fullname: Marigot-Outtandy, Dhiba organization: Bligny – sequence: 2 givenname: Xavier surname: Lescure fullname: Lescure, Xavier organization: Paris-Bichat – sequence: 3 givenname: Marie surname: Dubert fullname: Dubert, Marie organization: Paris-Bichat – sequence: 4 givenname: Yazdan surname: Yazdanpanah fullname: Yazdanpanah, Yazdan organization: Paris-Bichat – sequence: 5 givenname: Eric surname: Caumes fullname: Caumes, Eric organization: Paris-Pitié-Salpetrière – sequence: 6 givenname: Pascaline surname: Choinier fullname: Choinier, Pascaline organization: Paris-Pitié-Salpetrière – sequence: 7 givenname: Elie surname: Haddad fullname: Haddad, Elie organization: Paris-Pitié-Salpetrière – sequence: 8 givenname: Jakub surname: Kowalczyk fullname: Kowalczyk, Jakub organization: Mulhouse – sequence: 9 givenname: Hélène surname: Laurichesse fullname: Laurichesse, Hélène organization: Clermont Ferrand – sequence: 10 givenname: Olivier surname: Lesens fullname: Lesens, Olivier organization: Clermont Ferrand – sequence: 11 givenname: Alexandra surname: Aubry fullname: Aubry, Alexandra organization: Paris-CNR Mycobactéries – sequence: 12 givenname: Isabelle surname: Bonnet fullname: Bonnet, Isabelle organization: Paris-CNR Mycobactéries – sequence: 13 givenname: Florence surname: Morel fullname: Morel, Florence organization: Paris-CNR Mycobactéries
Copyright	2022 Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml	– notice: 2022 – notice: Distributed under a Creative Commons Attribution 4.0 International License
CorporateAuthor	TBnet, The ESGMYC, and The French MDR-TB Group
CorporateAuthor_xml	– name: TBnet, The ESGMYC, and The French MDR-TB Group
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES
DOI	10.1016/j.jinf.2022.03.004
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	1532-2742
EndPage	872
ExternalDocumentID	oai:HAL:hal-03608140v1 35271917 10_1016_j_jinf_2022_03_004 S016344532200130X
Genre	Letter Correspondence
GroupedDBID	--- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGAM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMK HMO HVGLF HZ~ IHE J1W J5H KOM L7B LUGTX M27 M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSI SSZ T5K UHS VH1 WUQ YHZ Z5R ZGI ~G- ~HD 0SF AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW LCYCR RIG 9DU AAYXX CITATION GROUPED_DOAJ CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES
ID	FETCH-LOGICAL-c485t-39b5a7d8e2b449bbd2843369fcf65a6bbc06bb633665a7fa0e4a8fe105b527723
ISICitedReferencesCount	6
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000903965100009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0163-4453 1532-2742
IngestDate	Tue Oct 14 20:48:15 EDT 2025 Tue Sep 30 23:51:49 EDT 2025 Wed Feb 19 02:26:14 EST 2025 Tue Nov 18 20:24:47 EST 2025 Sat Nov 29 07:21:55 EST 2025 Fri Feb 23 02:37:14 EST 2024 Tue Oct 14 19:31:00 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	MDR antiviral tuberculosis
Language	English
License	Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c485t-39b5a7d8e2b449bbd2843369fcf65a6bbc06bb633665a7fa0e4a8fe105b527723
Notes	content type line 23 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1
ORCID	0000-0001-9330-019X 0000-0003-0886-9635 0000-0001-5660-6544 0000-0001-8360-4376 0000-0001-8184-6291 0000-0002-4943-4446 0000-0002-9691-4741 0000-0002-3879-1480 0000-0001-7378-2179
OpenAccessLink	https://hal.sorbonne-universite.fr/hal-03608140
PMID	35271917
PQID	2638723912
PQPubID	23479
PageCount	39
ParticipantIDs	hal_primary_oai_HAL_hal_03608140v1 proquest_miscellaneous_2638723912 pubmed_primary_35271917 crossref_citationtrail_10_1016_j_jinf_2022_03_004 crossref_primary_10_1016_j_jinf_2022_03_004 elsevier_sciencedirect_doi_10_1016_j_jinf_2022_03_004 elsevier_clinicalkey_doi_10_1016_j_jinf_2022_03_004
PublicationCentury	2000
PublicationDate	2022-06-01
PublicationDateYYYYMMDD	2022-06-01
PublicationDate_xml	– month: 06 year: 2022 text: 2022-06-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	The Journal of infection
PublicationTitleAlternate	J Infect
PublicationYear	2022
Publisher	Elsevier Ltd Elsevier
Publisher_xml	– name: Elsevier Ltd – name: Elsevier
References	Carvalho, Pillai, Daniels, Sellers, Whyte, Eveson (bib0001) 2020; 80 Behzadifar, Heydarvand, Behzadifar, Bragazzi (bib0004) 2019; 29 (bib0003) 2020 Seung, Franke, Hewison, Huerga, Khan, Mitnick (bib0005) 2020; 72 van Leth, Brinkmann, Cirillo, Dheda, Duarte, Guglielmetti (bib0010) 2019; 53 WHO, Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. (bib0006) 2018 Kempker, Alghamdi, Al-Shaer, Burch, Peloquin (bib0007) 2019 Musso, Mosti, Gualano, Mencarini, Urso, Ghirga (bib0009) 2019; 19 Melikyan, Huerga, Atshemyan, Kirakosyan, Sargsyants, Aydinyan (bib0008) 2021; 8 Seung (10.1016/j.jinf.2022.03.004_bib0005) 2020; 72 Musso (10.1016/j.jinf.2022.03.004_bib0009) 2019; 19 Kempker (10.1016/j.jinf.2022.03.004_bib0007) 2019 Melikyan (10.1016/j.jinf.2022.03.004_bib0008) 2021; 8 10.1016/j.jinf.2022.03.004_bib0002 (10.1016/j.jinf.2022.03.004_bib0003) 2020 van Leth (10.1016/j.jinf.2022.03.004_bib0010) 2019; 53 Carvalho (10.1016/j.jinf.2022.03.004_bib0001) 2020; 80 Behzadifar (10.1016/j.jinf.2022.03.004_bib0004) 2019; 29 (10.1016/j.jinf.2022.03.004_bib0006) 2018
References_xml	– volume: 29 start-page: 945 year: 2019 end-page: 956 ident: bib0004 article-title: Prevalence of hepatitis C Virus in tuberculosis patients: a systematic review and meta-analysis publication-title: Ethiop J Health Sci – year: 2019 ident: bib0007 article-title: A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment publication-title: Antimicrob Agents Chemother – volume: 80 start-page: 232 year: 2020 end-page: 254 ident: bib0001 article-title: Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience publication-title: J Infect – volume: 19 start-page: 882 year: 2019 ident: bib0009 article-title: Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis publication-title: BMC Infect Dis – volume: 72 start-page: 1028 year: 2020 end-page: 1029 ident: bib0005 article-title: High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients publication-title: J Hepatol – volume: 8 start-page: ofaa653 year: 2021 ident: bib0008 article-title: Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe publication-title: Open Forum Infect Dis – volume: 53 year: 2019 ident: bib0010 article-title: The tuberculosis network European trials group (TBnet) ERS clinical research collaboration: addressing drug-resistant tuberculosis through European cooperation publication-title: Eur Respir J – reference: WHO, Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. – year: 2018 ident: bib0006 article-title: Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection – year: 2020 ident: bib0003 article-title: Global Tuberculosis Report 2020 – volume: 80 start-page: 232 year: 2020 ident: 10.1016/j.jinf.2022.03.004_bib0001 article-title: Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience publication-title: J Infect doi: 10.1016/j.jinf.2019.10.019 – volume: 29 start-page: 945 year: 2019 ident: 10.1016/j.jinf.2022.03.004_bib0004 article-title: Prevalence of hepatitis C Virus in tuberculosis patients: a systematic review and meta-analysis publication-title: Ethiop J Health Sci – year: 2018 ident: 10.1016/j.jinf.2022.03.004_bib0006 – volume: 72 start-page: 1028 year: 2020 ident: 10.1016/j.jinf.2022.03.004_bib0005 article-title: High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients publication-title: J Hepatol doi: 10.1016/j.jhep.2019.10.018 – ident: 10.1016/j.jinf.2022.03.004_bib0002 – year: 2019 ident: 10.1016/j.jinf.2022.03.004_bib0007 article-title: A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01215-19 – volume: 53 year: 2019 ident: 10.1016/j.jinf.2022.03.004_bib0010 article-title: The tuberculosis network European trials group (TBnet) ERS clinical research collaboration: addressing drug-resistant tuberculosis through European cooperation publication-title: Eur Respir J doi: 10.1183/13993003.02089-2018 – year: 2020 ident: 10.1016/j.jinf.2022.03.004_bib0003 – volume: 19 start-page: 882 year: 2019 ident: 10.1016/j.jinf.2022.03.004_bib0009 article-title: Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis publication-title: BMC Infect Dis doi: 10.1186/s12879-019-4494-1 – volume: 8 start-page: ofaa653 year: 2021 ident: 10.1016/j.jinf.2022.03.004_bib0008 article-title: Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofaa653
SSID	ssj0009396
Score	2.3768628
Snippet	ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The...
SourceID	hal proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	834
SubjectTerms	Antitubercular Agents - therapeutic use Hepatitis C - drug therapy Human health and pathology Humans Infectious diseases Life Sciences Pulmonology and respiratory tract Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy
Title	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S016344532200130X https://dx.doi.org/10.1016/j.jinf.2022.03.004 https://www.ncbi.nlm.nih.gov/pubmed/35271917 https://www.proquest.com/docview/2638723912 https://hal.sorbonne-universite.fr/hal-03608140
Volume	84
WOSCitedRecordID	wos000903965100009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1532-2742 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009396 issn: 0163-4453 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbaDU2TEILBoAMmg3irUrWxc-OtLWVl2qZJK6g8WbaTiFVtWnVttf-xP8xx7DgtowMeeIla3xL5fLaP7e-cg9AH0FJjKkFz81spdWgsCYy5lDiScEmCNEpakubBJoKLi3A4jC4rlbvCFmY1DrIsvL2NZv9V1JAGwlams_8gbtsoJMBvEDo8Qezw_CvBd6cO3_CIm9MALJ9c0Qrn1ymfzNSdugO7baVBQsago23ctLfcer_7zTK1Mm2_PuhkiSak965Ozr9313zTjkrQna77ojD1SxYHzKw5f-AKMFLe6H9S9_WdjibZT1TkgTObByAe8zxAeP3ExPq2Roz6ImXKM-eSL9cPMGDva4lWjaSYdJWJEN2YlXXgOIO-9SnWHH7em_r1KcSoMYLUhnqPdl67URh6azbJ5Q56Z6C2quUyaMmJRVYV7bqBF8FUudv-0huelr6cSeQb-ytNFfz1lftor2hkm7pT_aF4t9s2NblyM3iKnhiR4bZG0zNUSbIDtHdueBcH6LE-3cXaaO05yu6BDE9TbEGGAWT4dyDDgw4G_GADMgwgwxYkH3Eb5xDLi2iI4RxiL9DXz71Bt--YyB2OpKG3cEgkPB7EYeIKSiMhYlCCCPGjVKa-x30hZBMePiTB3yDlzYTyME1A1xfQb4FLDtFOBih8hXCTuDIllMaU-1T4ccSFJ1zCqStiKgKvhlpFBzNp3Nqr6CpjVvAXR0zJhyn5sCZhIJ8aqts6M-3U5cHSpJAbK8yVYYFlALwHa3m2llFmtZL6x3rvARr2s5T39377jKk0UDabykHdqlVD7wrkMFgO1B0fz5Lp8oa5sJ5C_0Utt4ZeakjZtgpMHm3NeY32yxH6Bu0s5svkLXokV4vrm_kxqgbD8NiMhp-IE9dS
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Co-administration+of+treatment+for+rifampicin-resistant+TB+and+chronic+HCV+infection%3A+A+TBnet+and+ESGMYC+study&rft.jtitle=The+Journal+of+infection&rft.au=Tunesi%2C+Simone&rft.au=D%C3%BB%2C+Damien+Le&rft.au=Gualano%2C+Gina&rft.au=Millet%2C+Joan-Pau&rft.date=2022-06-01&rft.eissn=1532-2742&rft.volume=84&rft.issue=6&rft.spage=834&rft_id=info:doi/10.1016%2Fj.jinf.2022.03.004&rft_id=info%3Apmid%2F35271917&rft.externalDocID=35271917
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-4453&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-4453&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-4453&client=summon